03

Aug2021

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision with Significant Implications for the New PMPRB Guidelines In a unanimous July 29 decision, the Federal Court of Appeal (FCA) overturned a Federal Court judicial review and quashed the PMPRB decision in ... Read More

26

Jul2021

Deadline Extended: PMPRB Notice and Comment

Deadline Extended: PMPRB Notice and Comment - New Price Tests for Grandfathered Medicines On July 15th, 2021, the PMPRB invited stakeholders to comment on three amendments to the regulations with responses due by August 15th 2021. PMPRB announced today that the deadline has been ... Read More

29

Jun2021

Welcome Jessica Birrell and Rachel Arcand to the PDCI Team!

PDCI Market Access has further expanded its Market Access Team! Jessica joins PDCI as Manager, Market Access.  She will be responsible for coordinating our pricing and market access projects including HTA and payer ... Read More

06

May2021

PMPRB Announces the Guideline Monitoring and Evaluation Plan (GMEP) Consultation

The PMPRB is developing a Guideline Monitoring and Evaluation Plan (GMEP) that will analyze trends in the pharmaceutical market before and after the implementation of the new framework to assess whether it is working as intended, and to inform the need for any future adjustments. The PMPRB ... Read More

14

Apr2021

NACI Process For Incorporating Economic Evidence Into Federal Vaccine Recommendations Consultation

BACKGROUNDThe National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.Traditionally, NACI reviewed safety, efficacy, immunogenicity, effectiveness and burden of illness in making recommendations for vaccine programs. PHAC has now expanded ... Read More

29

Mar2021

CADTH Releases Pharmaceuticals Reviews Update – Issue 22

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CADTH reimbursement review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.... Read More

15

Jan2021

PMPRB Proposes Amendments to New Guidelines: Requests Consultation from Stakeholders

On January 13th 2021, as a consequence of the new PMPRB coming-into-force date, PMPRB has invited stakeholders to comment on two proposed amendments to the New Guidelines.  The two amendments pertain to (A) the Definition of Gap Medicines and (B) Compliance Timelines with Maximum List ... Read More

15

Jan2021

Released: PMPRB11 Potential Sources for Foreign Prices

The PMPRB has released a list of potential sources for prices in the PMPRB 11 basket of reference countries. A non-exhaustive list of examples of potential foreign sources can be found here. Starting July 1, 2021, the Patented Medicines Regulations will require patentees to ... Read More

08

Jan2021

Welcome Piraveena Sabesan to PDCI Market Access

We’re pleased to introduce you to newest member of the PDCI team, Piraveena Sabesan, in her role as Associate, HTA and Health Economics! Piraveena holds a Master of Biotechnology (Biopharmaceuticals) from the University of ... Read More

08

Dec2020

PMPRB Webinar on Online Filing Tool (December 7, 2020) – Attachment Included

Today the PMPRB hosted a webinar for their new online filing tool which will be available to all patentees as of January 1st, 2021. The webinar revealed a new Form 4 (which will provide PMPRB with the National Market size estimation for new medicines) along with a walk through of the ... Read More